[go: up one dir, main page]

MA51056A - Compositions et méthodes pour le traitement d'affections métaboliques - Google Patents

Compositions et méthodes pour le traitement d'affections métaboliques

Info

Publication number
MA51056A
MA51056A MA051056A MA51056A MA51056A MA 51056 A MA51056 A MA 51056A MA 051056 A MA051056 A MA 051056A MA 51056 A MA51056 A MA 51056A MA 51056 A MA51056 A MA 51056A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
metabolic disorders
metabolic
Prior art date
Application number
MA051056A
Other languages
English (en)
Inventor
Brian David Denomme
James Ervin
Peter Pacult
Wyk Hendrik Johanness Petrus Van
Wyk Mariette Luise Van
Michael A Volk
Original Assignee
Reven Ip Holdco Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reven Ip Holdco Llc filed Critical Reven Ip Holdco Llc
Publication of MA51056A publication Critical patent/MA51056A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051056A 2017-12-07 2018-12-07 Compositions et méthodes pour le traitement d'affections métaboliques MA51056A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762595909P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MA51056A true MA51056A (fr) 2020-10-14

Family

ID=66750649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051056A MA51056A (fr) 2017-12-07 2018-12-07 Compositions et méthodes pour le traitement d'affections métaboliques

Country Status (18)

Country Link
US (3) US20200289553A1 (fr)
EP (1) EP3720421A4 (fr)
JP (2) JP2021505673A (fr)
KR (1) KR102546138B1 (fr)
CN (1) CN111565709A (fr)
AU (1) AU2018379078A1 (fr)
BR (1) BR112020011417A2 (fr)
CA (1) CA3084369A1 (fr)
CL (1) CL2020001495A1 (fr)
CR (1) CR20200291A (fr)
EA (1) EA202091396A1 (fr)
IL (1) IL275182B2 (fr)
JO (1) JOP20200134A1 (fr)
MA (1) MA51056A (fr)
MX (1) MX2020005879A (fr)
PH (1) PH12020550788A1 (fr)
SG (1) SG11202005158PA (fr)
WO (1) WO2019113543A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
US20200390743A1 (en) * 2019-06-12 2020-12-17 Reven Ip Holdco Llc Methods and Compositions For Improving Outcomes of Cancer Patients
MX2023003725A (es) * 2020-09-30 2023-06-28 Reven Pharmaceuticals Inc Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación.
KR102527526B1 (ko) 2020-11-06 2023-05-02 충북대학교 산학협력단 Ｌｓｔｍ 기반 구조물의 동적특성 자동추출방법 및 이를 수행하는 시스템
CA3209890A1 (fr) * 2021-02-26 2022-09-01 Kumaresh Soppimath Formulation injectable de bicarbonate de sodium et methodes d'utilisation associees
KR102505980B1 (ko) * 2021-11-12 2023-03-06 알고케어 주식회사 사용자의 현재 건강 상태에 최적화된 제형의 조합을 제공하는 디스펜싱 디바이스와 서버 및 그 동작 방법
AU2023205178B2 (en) 2022-01-04 2025-09-25 Renovion, Inc. Aqueous solution comprising a glutathione salt
US11925703B1 (en) 2022-07-29 2024-03-12 Xellia Pharmaceuticals Aps Liquid composition comprising glucose
CN120344246A (zh) * 2022-12-15 2025-07-18 玛氏公司 治疗马科动物垂体中间部功能障碍（ppid）的维生素b补充剂
US20250049842A1 (en) * 2023-07-13 2025-02-13 James D. Ervin Therapeutic blood-acid-shifting compositions and methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080886A (en) * 1990-01-05 1992-01-14 Sterling Drug Inc. Pharmaceutical compositions for the prevention and treatment of oxidant injuries
EP0746202A4 (fr) * 1992-01-06 1997-06-25 Health Maintenance Programs Composition contenant un anti-oxydant pharmaceutiquement actif et son procede d'utilisation dans la prevention et le traitement d'une restenose apres angioplastie
JPH0959150A (ja) * 1995-08-11 1997-03-04 Roussel Morishita Kk 経静脈用輸液製剤
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP2003501488A (ja) 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US20040110684A1 (en) 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
AU2001222986A1 (en) * 2000-05-19 2001-12-03 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US7122210B2 (en) * 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
WO2005044176A2 (fr) 2003-11-10 2005-05-19 Lipogen Ltd. Compositions contenant un acide phosphatidique et leurs procedes d'utilisation et de production, et articles de fabrication contenant lesdites compositions
JP2005179200A (ja) * 2003-12-16 2005-07-07 Terumo Corp ビタミンｂ１類配合輸液剤
JPWO2005084660A1 (ja) * 2004-03-05 2007-08-09 森重 文江 ミトコンドリア病予防と対策
DE102004023828A1 (de) * 2004-05-13 2005-12-08 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
JP4615470B2 (ja) 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
CN101209344B (zh) * 2006-12-28 2012-07-04 赵超英 高渗液组合物在制备促进伤口愈合的药物中的应用
MX2009007200A (es) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
WO2009152374A2 (fr) * 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Procédé de traitement de plaies chroniques
WO2010011927A1 (fr) 2008-07-25 2010-01-28 Noventis, Inc. Compositions et procédés pour la prévention et le traitement de maladies cardiovasculaires
EP2456432B1 (fr) 2009-07-22 2024-02-28 University of Massachusetts Compositions pour réduire le stress oxydatif
WO2011013138A1 (fr) * 2009-07-29 2011-02-03 Strides Arcolab Limited Formulations multi-vitaminiques stables
ES2661539T3 (es) * 2009-10-15 2018-04-02 Purecircle Sdn Bhd Rebaudiósido D de pureza elevada y aplicaciones
PL2324832T5 (pl) * 2009-11-09 2017-10-31 Biogena Naturprodukte Gmbh & Co Kg Suplement diety przy przyjmowaniu hormonalnych środków antykoncepcyjnych
CN107095847A (zh) * 2010-05-07 2017-08-29 Ea制药株式会社 混合有维生素的外周静脉给药用营养输液
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
CN103327986B (zh) * 2010-07-22 2018-05-25 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法
KR20130021958A (ko) * 2011-08-24 2013-03-06 울산대학교 산학협력단 인공 수액
US20150196708A1 (en) * 2012-08-17 2015-07-16 The Regents Of The University Of California Systems, methods and compositions for improved treatment of acidosis
CN105579464B (zh) 2013-08-07 2021-01-26 耶达研究及发展有限公司 能够再活化p53突变体的肽
CN106924744A (zh) * 2015-12-30 2017-07-07 钟术光 一种供注射或口服用的药物载体(或制剂)
WO2017143446A1 (fr) * 2016-02-23 2017-08-31 Mitronite Inc. Compositions et méthodes pour améliorer la fonction mitochondriale

Also Published As

Publication number Publication date
WO2019113543A1 (fr) 2019-06-13
AU2018379078A1 (en) 2020-07-23
EP3720421A4 (fr) 2021-09-15
CR20200291A (es) 2020-11-18
JP2023134671A (ja) 2023-09-27
EP3720421A1 (fr) 2020-10-14
BR112020011417A2 (pt) 2020-11-24
CA3084369A1 (fr) 2019-06-13
IL275182B2 (en) 2024-04-01
CN111565709A (zh) 2020-08-21
KR102546138B1 (ko) 2023-06-23
US11344529B2 (en) 2022-05-31
US20200289553A1 (en) 2020-09-17
US20200121640A1 (en) 2020-04-23
EA202091396A1 (ru) 2020-09-02
US20210322373A1 (en) 2021-10-21
MX2020005879A (es) 2020-10-07
IL275182A (en) 2020-07-30
JP2021505673A (ja) 2021-02-18
KR20200097757A (ko) 2020-08-19
CL2020001495A1 (es) 2021-02-19
PH12020550788A1 (en) 2021-04-19
IL275182B1 (en) 2023-12-01
JOP20200134A1 (ar) 2022-10-30
SG11202005158PA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3368088C0 (fr) Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3661553A4 (fr) Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
EP3762505A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3641746A4 (fr) Méthodes et compositions pour le traitement d'une infection microbienne
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3810091A4 (fr) Méthodes et compositions pour le traitement de l'hypertension pulmonaire
EP3400008A4 (fr) Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3442554A4 (fr) Compositions et méthodes pour le traitement de troubles associés à la néovascularisation
EP3638270A4 (fr) Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie